Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists
Open Access
- 20 June 2018
- journal article
- research article
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 16 (1) , 38
Abstract
Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease with broad variations of the individual course. Data on the optimal management are mostly lacking. Currently treatment decisions are often based on experts’ opinions. In order to develop consensus-based treatment strategies for JDM in Germany a survey was pursued to analyze the current clinical practice. An online survey addressing all members of the Society for Pediatric Rheumatology (GKJR) in Germany and Austria and pediatric neurologists with expertise in JDM was performed in February/March of 2016. The questionnaire consisted of 5 case scenarios including diagnostic criteria, treatment of moderate, severe and refractory JDM, using either multiple choice or a 5-point Likert scale. Basic descriptive statistics were used to analyze the findings. The survey was completed by 60 pediatric rheumatologists and 7 pediatric neurologists experienced in the management of JDM. Typical findings allowing a diagnosis were considered to be: typical skin changes, proximal muscle weakness, MRI findings, elevated muscle enzymes, nailfold capillary changes, presence of calcinosis and muscle biopsy. Regarding induction treatment of moderate/severe JDM: 59%/74% opted for intermittent intravenous methylprednisolone (IVMP) pulse therapy, and 21%/40% for conventional high-dose oral glucocorticoids. Methotrexate (MTX) was the preferred disease-modifying conventional anti-rheumatic drug (cDMARD) for moderate and severe JDM. Regarding the management of refractory moderate or severe JDM, intravenous immune globulins, mycophenolate mofetil and rituximab were preferred treatment options. There is consensus about the diagnosis of JDM strongly supported by classic clinical and MRI findings. There is great variety in the treatment of JDM in Germany regarding both induction and maintenance therapy. The development of consensus-based treatment strategies for JDM based on harmonization of current clinical practice is essential in order to allow comparative effectiveness research in the future.Keywords
Funding Information
- Initiative für das rheumakranke Kind (Not applicable)
- U can ride for arthritis (Not applicable)
This publication has 38 references indexed in Scilit:
- Cardiac findings in children with juvenile Dermatomyositis at disease presentationPediatric Rheumatology, 2017
- Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North AmericaPediatric Rheumatology, 2017
- The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomesJournal of Internal Medicine, 2016
- Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trialThe Lancet, 2016
- Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus ConferenceArthritis Care & Research, 2011
- Juvenile Dermatomyositis: Correlation of MRI at Presentation With Clinical OutcomeAmerican Journal of Roentgenology, 2011
- Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositisArthritis Care & Research, 2008
- Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositisRheumatology, 2007
- Juvenile DermatomyositisZeitschrift für Rheumatologie, 2006
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975